| Prognostic usefulness of serial C-reactive protein measurements in ST-elevation acute myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 23040593 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
It has been reported that increased levels of C-reactive protein are related to adverse long-term prognosis in the setting of ST-segment elevation acute myocardial infarction (MI). In previous studies, the timing of C-reactive protein determination has varied widely. In the present study, serial high-sensitivity C-reactive protein (hsCRP) measurements were performed to investigate if any of the measurements is superior regarding long-term prognosis. A total of 861 consecutive patients admitted for ST-segment elevation MI and treated with intravenous thrombolysis within the first 6 hours from the index pain were included. HsCRP levels were determined at presentation and at 24, 48, and 72 hours. The median follow-up time was 3.5 years. New nonfatal MI and cardiac death were the study end points. By the end of follow-up, cardiac death was observed in 22.4% and nonfatal MI in 16.1% of the patients. HsCRP levels were found to be increasing during the first 72 hours. Multivariate Cox regression analysis demonstrated that hsCRP levels at presentation were an independent predictor of the 2 end points (relative risk [RR] 2.8, p = 0.002, and RR 2.1, p = 0.03, for MI and cardiac death, respectively), while hsCRP levels at 24 hours did not yield statistically significant results (RR 1.4, p = 0.40, and RR 1.1, p = 0.80, for MI and cardiac death, respectively). The corresponding RRs at 48 hours were 1.2 (p = 0.5) for MI and 3.2 (p = 0.007) for cardiac death and at 72 hours were 1.6 (p = 0.30) for MI and 3.9 (p <0.001) for cardiac death. In conclusion, hsCRP levels at presentation represent an independent predictor for fatal and nonfatal events during long-term follow-up. HsCRP levels at 48 and 72 hours, which are close to peak hsCRP levels, independently predict only cardiac death. |
| | |
Authors:
|
Stamatis S Makrygiannis; Olga S Ampartzidou; Michael N Zairis; Nikolaos G Patsourakos; Christos Pitsavos; Dimitris Tousoulis; Athanasios A Prekates; Stefanos G Foussas; Dennis V Cokkinos |
Related Documents
:
|
21188623 - Matrix metalloproteinases and membrane damage markers in sera of patients with acute my... 21148653 - Coronary stents: factors contributing to perioperative major adverse cardiovascular eve... 22266053 - Unusual adverse consequence of reverse ventricular remodelling following cardiac resync... |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2012-10-02 |
Journal Detail:
|
Title: The American journal of cardiology Volume: 111 ISSN: 1879-1913 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2012-12-18 Completed Date: 2013-02-14 Revised Date: 2013-04-23 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 26-30 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2013 Elsevier Inc. All rights reserved. |
Affiliation:
|
Cardiology Department, Tzanio Hospital of Piraeus, Piraeus, Greece. ssmakrygiannis@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Markers
/
blood C-Reactive Protein / metabolism* Cause of Death / trends Electrocardiography* Female Follow-Up Studies Greece / epidemiology Humans Male Middle Aged Myocardial Infarction / blood*, diagnosis, mortality Prognosis Retrospective Studies Severity of Illness Index Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 9007-41-4/C-Reactive Protein |
| Comments/Corrections | |
Comment In:
|
Am J Cardiol. 2013 Apr 1;111(7):1079-80
[PMID:
23498089
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Angiographic Features and Cardiovascular Risk Factors in Human Immunodeficiency Virus-Infected Patie...
Next Document: Safety and Efficacy of Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Women.